Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

Tumors can recur years after treatment, and breast cancer is especially noted for long periods of dormancy. The status of the cancer during this period is poorly understood. As a model to study mechanisms of dormancy, we used murine D2.0R mammary carcinoma cells, which are poorly metastatic but form occasional metastases in liver and other organs after long latency. Highly metastatic D2A1 cells provided a positive, metastatic control. Our goals were to learn how the cell lines differ in survival kinetics in a secondary site and to seek evidence for the source of D2.0R dormancy. In spontaneous metastasis assays from mammary fat pad injections, we found evidence for dormancy because of a persistence of large numbers of solitary cells in the liver. To quantify the fate of cells after arrival in liver, experimental metastasis assays were used. To permit identification of cells that had not divided, cells were labeled before injection with fluorescent nanospheres, which were diluted to undetectable levels by cell division. Cancer cells were injected i.v. to target them to the liver and coinjected with reference microspheres to monitor cell survival. Dormancy was defined as retention of nanosphere fluorescence in vivo, as well as negative staining for the proliferation marker Ki67. A large proportion of D2.0R cells persisted as solitary dormant cells. No metastases formed, but viable cells could be recovered from the liver 11 weeks after injection. Large numbers of solitary, dormant, Ki67-negative D2A1 cells were also detected against a background of progressively growing metastases. Thus, this study identified a possible contributor to tumor dormancy: solitary, dormant cells that persist in tissue. If such cells are present in patients, they could contribute to tumor recurrence and would not be susceptible to current therapeutic strategies targeting proliferating cells.

[1]  V. Morris,et al.  Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines , 2004, Clinical & Experimental Metastasis.

[2]  H. Seigler,et al.  Relationship between disease-free interval and survival in patients with recurrent melanoma. , 1992, Archives of surgery.

[3]  E. Weibel Stereological Methods. Practical methods for biological morphometry , 1979 .

[4]  L. Ossowski,et al.  Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy , 1997, The Journal of cell biology.

[5]  Christopher W. Wong,et al.  Apoptosis: an early event in metastatic inefficiency. , 2001, Cancer research.

[6]  A. K. Laird,et al.  Dynamics of growth in tumors and in normal organisms. , 1969, National Cancer Institute monograph.

[7]  Yeu‐Tsu N. Lee,et al.  Breast carcinoma: Pattern of metastasis at autopsy , 1983, Journal of surgical oncology.

[8]  Immune mechanisms and tumor dormancy. , 1996, Medicina.

[9]  W. Stadler,et al.  Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. , 1998, Cancer research.

[10]  J. Pickren,et al.  Metastases from carcinoma of mammary gland: An autopsy study , 1979, Journal of surgical oncology.

[11]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[12]  J. Leith,et al.  Dormancy, regression, and recurrence: towards a unifying theory of tumor growth control. , 1994, Journal of theoretical biology.

[13]  K. Luzzi,et al.  Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.

[14]  B. Zbar,et al.  Clonality of pulmonary metastases from the bladder 6 subline of the B16 melanoma studied by southern hybridization. , 1987, Journal of the National Cancer Institute.

[15]  J E Talmadge,et al.  Evidence for the clonal origin of spontaneous metastases. , 1982, Science.

[16]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[17]  R. Demicheli,et al.  Proposal for a new model of breast cancer metastatic development. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.

[19]  I. Macdonald,et al.  Clinical targets for anti-metastasis therapy. , 2000, Advances in cancer research.

[20]  A. Meltzer,et al.  Dormancy and breast cancer , 1990, Journal of surgical oncology.

[21]  S. Koscielny,et al.  Re: Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[22]  I. Macdonald,et al.  Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. , 2000, Cancer research.

[23]  C. Murray Tumour dormancy: not so sleepy after all , 1995, Nature Medicine.

[24]  R. Demicheli,et al.  Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[25]  Stewart Th Immune mechanisms and tumor dormancy. , 1996 .

[26]  I. Macdonald,et al.  Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis , 1993, Clinical & Experimental Metastasis.

[27]  V. Ling,et al.  A model system for studying metastasis using the embryonic chick. , 1982, Cancer research.

[28]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[29]  Robert H. Wardwell,et al.  Computer simulation of a breast cancer metastasis model , 1997, Breast Cancer Research and Treatment.

[30]  U. Bagge,et al.  Lethal deformation of cancer cells in the microcirculation: A potential rate regulator of hematogenous metastasis , 1992, International journal of cancer.

[31]  D. Welch,et al.  Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate , 2004, Clinical & Experimental Metastasis.

[32]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[33]  M. Retsky,et al.  A stochastic numerical model of breast cancer growth that simulates clinical data. , 1984, Cancer research.

[34]  D J Ferguson,et al.  Dormancy of mammary carcinoma after mastectomy. , 1999, Journal of the National Cancer Institute.

[35]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[36]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.